Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential

Osteosarcoma is the most common primary malignant bone tumor and is associated with a high risk of recurrence and distant metastasis. Effective treatment for osteosarcoma, especially advanced osteosarcoma, has stagnated over the past four decades. The advent of immune checkpoint inhibitor (ICI) has...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2022-10, Vol.547, p.215887-215887, Article 215887
Main Authors: Wen, Yang, Tang, Fan, Tu, Chongqi, Hornicek, Francis, Duan, Zhenfeng, Min, Li
Format: Article
Language:English
Subjects:
Antigens
Apoptosis
Bone cancer
Bone tumors
Cancer therapies
Cell death
Chemotherapy
Clinical trials
CTLA-4
CTLA-4 protein
Cytotoxicity
FDA approval
Immune checkpoint
Immune checkpoint inhibitor
Immune checkpoint inhibitors
Immunotherapy
Ligands
Lymphocytes
Lymphocytes T
Lymphoma
Medical prognosis
Melanoma
Metastases
Metastasis
Osteosarcoma
PD-1 protein
PD-L1
PD-L1 protein
Proteins
Sarcoma
T cell receptors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteosarcoma is the most common primary malignant bone tumor and is associated with a high risk of recurrence and distant metastasis. Effective treatment for osteosarcoma, especially advanced osteosarcoma, has stagnated over the past four decades. The advent of immune checkpoint inhibitor (ICI) has transformed the treatment paradigm for multiple malignant tumor types and indicated a potential therapeutic strategy for osteosarcoma. In this review, we discuss recent advances in immune checkpoints, including programmed cell death protein-1 (PD-1), programmed cell death protein ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), and their related ICIs for osteosarcoma treatment. We present the main existing mechanisms of resistance to ICIs therapy in osteosarcoma. Moreover, we summarize the current strategies for improving the efficacy of ICIs in osteosarcoma and address the potential predictive biomarkers of ICIs treatment in osteosarcoma. •Effective treatment for advanced osteosarcoma has stagnated over the past decades.•ICIs have transformed the treatment paradigm for multiple malignant tumor types.•Multiple mechanisms contribute to the ICIs resistance of osteosarcoma.•ICIs have indicated a potential therapeutic strategy for osteosarcoma.•Further biomarker studies are needed to identify patients most sensitive to ICIs.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2022.215887